Charles Schwab Investment Management Inc. Trims Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Charles Schwab Investment Management Inc. lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,773,397 shares of the biopharmaceutical company’s stock after selling 14,151 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.39% of Halozyme Therapeutics worth $101,509,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HALO. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after buying an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares during the period. Boston Trust Walden Corp purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $23,211,000. Swedbank AB purchased a new position in shares of Halozyme Therapeutics during the 1st quarter worth $13,927,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $47.79 on Wednesday. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a market cap of $6.08 billion, a P/E ratio of 15.81, a P/E/G ratio of 0.45 and a beta of 1.29. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The stock has a fifty day moving average price of $54.28 and a 200 day moving average price of $53.68.

Analysts Set New Price Targets

HALO has been the topic of a number of recent analyst reports. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. TD Cowen increased their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. JMP Securities increased their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Benchmark restated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, HC Wainwright restated a “buy” rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, November 20th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total value of $590,900.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $39,988,802.96. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 60,000 shares of company stock worth $3,425,000. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.